Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model-Based Approach.

Clin Transl Sci · 2025 · PMC12033006 · PMID 40286320

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

There was a slight trend for a relationship between tislelizumab exposure and the probability of IRRs.

also in 2,443 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.